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Abstract
Potassium nitrate dentifrices (KNO3) have been used to treat the 
symptoms of dentine hypersensitivity (DH), however relatively few 
mouthrinse studies have been published. 
Aim
 The aim of this study was to compare a 5% KNO3 mouthrinse to a placebo 
control in an 8-week double-blind placebo-controlled study. 
Materials and Methods
Male and female subjects aged 18 to 65 years in good health and a history 
of Dentine Hypersensitivity were recruited for the study. Subjects were 
randomised and allocated into the test and control groups and instructed 
to use the mouthrinse twice a day after brushing with a regular family 
toothpaste using a small head soft toothbrush. The clinical evaluation of 
Dentine Hypersensitivity included 1) Subjective Sensitivity (Perception 
of overal sensitivity) using aVAS score, 2) Thermal Sensitivity response 
from a one second air blast from a dental air syringe using VAS Scores, 
3) Tactile Sensitivity Threshold Scores on the selected test teeth using a 
controlled force probe (gm. weight) and 4) Tactile Sensitivity at a Fixed 
Force of 40 gm. weight evaluating the remaining teeth to determine 
the existence of dentine sensitivity based on a simple yes/no response. 
Subjects were evaluated at baseline, four and eight weeks. 
Results
The 104 subjects recruited for the study, 103 subjects (35M; 68F mean 
age 34.6 years) completed the study. The results indicated that the tactile 
response demonstrated the clearest difference between the KNO3 mouth 
rinse and placebo.  Both the KNO3 and placebo mouth rinse showed an 
increase in the tactile sensitivity threshold (i.e. less sensitivity) at both 
evaluation time points with the increase in the tactile sensitivity threshold 
twice as high at Week 8 than at Week 4.  The increase in sensitivity 
threshold using KNO3 was twice as large as the increase with Placebo 
at both time points (6.79 g for KNO3 compared to 3.60g for Placebo at 
Week 4 and 11.80 g for KNO3 compared to 6.58 g for Placebo at Week 8) 
with a statistically significant difference (p = 0.031) at Week 8. Moreover, 
the efficacy of the KNO3 treatment was more apparent in subjects with 
a more severe condition of dentine hypersensitivity, as measured by the 
number of threshold sensitive teeth at baseline.  Among the 75 subjects 
with ≥ three tactile sensitive teeth, the active treatment was statistically 
significantly superior to placebo (p < 0.01) at both the Week 4 and Week 
8 evaluation points. 
Conclusion
These results therefore confirm the results of Gillam et al. (1996) by 
demonstrating that a 5% KNO3 mouthwash significantly reduced dentine 
hypersensitivity as measured by tactile stimulation.
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Introduction
Potassium nitrate (KNO3) has been used previously in a dentifrice or 
gel to treat the symptoms of dentine hypersensitivity (DH). There have 
been relative few published studies on the use of potassium containing 
mouthrinses. Of these published studies Gillam et al. [1] and Pereira & 
Chava [2] compared a 3% KNO3 mouthrinse to a control and suggested 
that KNO3 mouthrinses appear to have therapeutic potential to alleviate 
DH.  Efficacy for KNO3 rinses in reducing DH was also demonstrated in 
subjects following periodontal treatment (Martinez and Loscos [3] and 
Oteo et al. [4].  A study by Yates et al. [5] Comparing a 2% Potassium 
citrate mouthrinse with a base rinse minus actives placebo control also 
reported highly significant reductions in DH for both groups although 
due to the magnitude of the placebo response (30-40%) there were no 
significant differences between the two groups.
Aim
The aim of this clinical study was to compare a 5% KNO3 mouthrinse to a 
placebo control in an 8-week double-blind placebo-controlled study. 
Materials and Methods
Subjects who gave their oral and written informed consent and satisified 
both inclusion and exclusion criteria were entered into the study, which 
had local Joint Research and Ethics Committee (JREC [IRB]) approval. The 
study was conducted according to the guidelines for good clinical practice 
(GCP). All subjects were given an oral examination (DGG) to determine 
their suitability for the study. The clinical assessments were performed by 
DGG/AA who were trained and calibrated in these assessments prior to 
the commencement of the study.
Inclusion and Exclusion Criteria
 Male and female subjects aged 18 to 65 years selected for the study had to be 
in good health, and report sensitivity on the subjective, tactile and thermal 
scales, as described below.  Among the exclusion criteria for subjects were: 
(1) Chronic disease associated with intermittent or constant daily pain; (2) 
Regular use of a desensitizing dentifrice within 2 months before the start 
of the study; (3) A dental prophylaxis within 2 weeks of the projected start 
of the study; (4) Daily doses of certain medications, including analgesics, 
anticonvulsants, antihistamines, sedatives, tranquilizers, mood-altering 
drugs or antiinflammatory drugs; (5) Demonstration of gross oral neglect 
or the need for extensive dental therapy.
Subjects in the study were instructed to use the mouthrinse twice a day 
after brushing with a regular family toothpaste (Colgate Great Regular
 Flavour), using a small head soft toothbrush.
Four clinical evaluations of sensitivity were used:
Subjective Sensitivity 
 Subjects were asked to evaluate their typical perceived pain level due to 
dentine hypersensitivity using a 100 mm Visual Analog Scale (VAS).
Thermal Sensitivity: Each sensitive tooth was subjected to a one second 
application of cold air from a standard dental air syringe at 40-65 p.s.i. at a 
temperature of 19oC+ 3oC and the intensity of pain evoked was marked by 
the subject on a 100 mm Visual Analogue Scale (VAS).
Tactile Sensitivity Threshold: Each sensitive tooth was subjected to 
a variable force in grams using the Yeaple probe (Vine Valley Research, 
Middlesex, New York, USA) and the pain sensitivity threshold was 
recorded.
Tactile Sensitivity at a Fixed Force of 40 grams: All additional teeth 
were subject to a fixed force of 40 grams using the Yeaple probe and the 
existence of sensitivity was recorded as a yes/no variable. All subjects 
reporting an overall hypersensitivity score in the range of 30-80 mm on 
a 100 mm VAS at both the qualifying and baseline visit were eligible for 
the study. 
Tactile sensitive teeth were those with a positive response to a fixed force 
of 40 grams followed by a Yeaple probe threshold score in the range of 15-
50 grams.  Thermal sensitive teeth were those which displayed a response 
from 30-80 mm on the 100 mm VAS.  Selected subjects were to have at 
least one tactile sensitive tooth and a minimum of two thermal sensitive 
teeth.
Information on all adverse experiences or other on-going conditions 
occuring during the course of the study was collected, whether or not 
they were associated with the study product.  At each visit, subjects were 
questioned regarding the occurrence of side effects in such a way as to not 
lead or bias the subject’s response.
Sensitivity assessments were conducted at Baseline and at 4 and 8 weeks. 
Each subject received a diary to record the number of times they brushed 




Statistical results for both thermal and tactile efficacy were based on teeth 
other than incisors.  This was supported by suggestion in the literature that 
efficacy was difficult to demonstrate in incisor teeth, perhaps because of 
the bilateral innervation confounds the results [6].
Analyses of the primary efficacy measures based on the teeth were 
performed utilizing mixed linear models (implemented with SAS, PROC 
MIXED).  In these analyses the unit of analysis was the tooth within the 
subject and multiple teeth within the same subject were adjusted for. 
This was particularly important for the tactile measure in which a widely 
varying number of teeth were evaluated in different subjects (Table 1), 
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and therefore the analysis based on subject averages was not appropriate. 
The t-statistic reported for the three efficacy measures in (Tables 3-5) 
was the ratio of the mean change from baseline divided by its standard 
error and reported from the mixed linear model.   The significance level 
associated with the t-statistic represents the statistical significance of the 
change from baseline.
Results 
One hundred and four subjects were randomised and 103 subjects were 
considered intent-to-treat evaluable and included in the analyses.  Of the 
103 subjects (35M; 68F mean age 34.6 years) who completed the study, 31 
subjects (30%) were smokers.  The two treatment groups were comparable 
for all the demographic characteristics (Table 2). 
Subjective Response
For both treatment groups, the decrease in sensitivity from baseline 
was observed to be statistically significant at both Week 4 and Week 8. 
However, the subjective assessment of hypersensitivity did not show a 
difference between the two treatments at either Week 4 or Week 8 (Table 
3).
Thermal Response
Baseline levels of thermal sensitivity were comparable between the two 
treatment groups.  For both treatment groups, the decrease in sensitivity 
from baseline was observed to be statistically significant at both Week 4 
and Week 8.  Thermally sensitive teeth in subjects using the KNO3 rinse 
exhibited a greater reduction in thermal sensitivity at Week 4 than with 
Placebo whereas the reverse was true at Week 8.  Neither difference was 
statistically significant.
Tactile Response – Teeth Qualifying For Threshold Testing
At baseline, the teeth exposed to the KNO3 mouth rinse were numerically 
more sensitive than were the teeth exposed to the placebo (19.06 g versus 
20.21 g, p=.055).  The post-baseline comparisons were adjusted for this 
baseline difference. For both treatment groups, the decrease in sensitivity 
from baseline was observed to be statistically significant at both Week 4 
and Week 8.  Both KNO3 and Placebo showed an increase in the tactile 
sensitivity threshold (i.e. reduction in sensitivity) at both time points with 
the increase in the tactile sensitivity threshold being twice as high at Week 
8 as at Week 4.  The increase in the sensitivity threshold with KNO3 was 
twice as large as the increase with Placebo at both time points (6.79 g for 
KNO3 compared to 3.60g for Placebo at Week 4 and 11.80 g for KNO3 
compared to 6.58 g for Placebo at Week 8) with the difference at Week 8 
being statistically significant (p=.031). Moreover, as shown in (Table 6) 
the efficacy of the active treatment was more apparent in subjects with 
a more severe condition of dentine hypersensitivity, as measured by the 
number of threshold sensitive teeth at baseline.  For the 75 subjects with 
at least three tactile sensitive teeth, the active treatment was statistically 
significantly superior to placebo (p < 0.01) at both the Week 4 and Week 
8 evaluation points.
Safety
There were 5 events reported in 5 subjects, during the 8 weeks of the study. 
Only one event, a mouth ulcer considered to be mild and unrelated to the 
product, was reported in the KNO3 group; the other 4 reported events 
were in the placebo group.
Discussion
According to Orchardson & Gillam [7] formulations containing potassium 
salts (either in toothpaste, gels, solutions and mouthrinses) have been widely 
used for treating DH although the effectiveness of these formulations (in 
toothpaste form) in reducing DH has been questioned [8]. The regular use 
of a pre- or post-rinse mouthrinse following routine toothbrushing with a 
fluoride toothpaste may be more acceptable to consumers and it is feasible 
that a formulation containing potassium and fluoride may be beneficial 
not only for reducing symptoms of DH but also help prevent root caries in 
an adult population [1,9]. The question of whether a pre-rinse or a post-
rinse desensitising mouthrinse would be more effective was not addressed 
in this study and this may need to be resolved in further studies.
Evaluation of the pain response in clinical trials designed to assess the 
efficacy of desensitizing products, however, is problematic for the clinical 
assessor. This was due in part to the highly subjective nature of the problem 
as well as the influence of Hawthorne and placebo effects throughout the 
duration of the trial. The study by Yates et al. (5) highlighted this problem of 
the magnitude of the placebo response which has also been reported by other 
investigators [1, 10-12]. Other factors such as lack of statistical power (small 
sample size) and lack of standardization of the methodology used in clinical 
trials to determine treatment outcomes can also influence the results [13]. 
Efficacy for KNO3 rinses in reducing DH has been previously demonstrated 
in subjects following periodontal treatment (3-4) as well as in subjects 
with a history of DH (1-2). Both Gillam et al. (1) and  Pereira & Chava 
(2) evalauted a 3% KNO3 mouthrinse using similar methodology with the 
exception of the tactile evaluation over 6-8 weeks product use.  In the 
Gillam et al. study (1) the clearest difference between the two treatments 
was demonstrated on the tactile scale, whereas Pereira & Chava (2) 
demonstrated significant differences in both the Overall sensitivity and 
Thermal scales. The present study appeared to confirm the findings of 
the Gillam et al. study (1) in that the tactile response demonstrated the 
clearest difference between the KNO3 mouthrinse and placebo.  Both 
KNO3 and placebo showed an increase in the tactile sensitivity threshold 
(i.e. less sensitivity) at both evaluation time points with the increase in 
the tactile sensitivity threshold twice  as high at Week 8 than at Week 4. 
The increase in sensitivity threshold using KNO3 was twice as large as the 
increase with Placebo at both time points (6.79 g for KNO3 compared to 
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3.60g for Placebo at Week 4 and  11.80 g for KNO3 compared to 6.58 g for 
Placebo at Week 8) with a statistically significant difference (p = 0.031) at 
Week 8 
Moreover, the efficacy of the KNO3 treatment was more apparent in 
subjects with a more severe condition of dentine hypersensitivity, as 
measured by the number of threshold sensitive teeth at baseline.  Among 
the 75 subjects with at least three tactile sensitive teeth, the active 
treatment was statistically significantly superior to placebo (p < 0.01) at 
both the Week 4 and Week 8 evaluation points.
Conclusions
The results from the present 8-week clinical study appear to demonstrate 
that rinsing with a 5% KNO3 mouthrinse following toothbrushing may 
alleviate DH, particularly in those individuals with more severe DH. 
Furthermore, the results confirmed the results of Gillam et al. (1) by 
demonstrating that the 5% KNO3 mouthrinse significantly reduced DH as 















Table 1: Number of Threshold Sensitive Teeth (Non-incisors) per Subject
Characteristics KNO3 Rinse Placebo TOTAL P-Value



























37 ( 72.5%)  
21 ( 40.4%)
31 ( 59.6%)  
35 ( 34.0%)
68 ( 66.0%) 0.213







39 ( 76.5%)  
6 ( 11.8%)  
2 (  3.9%) 
4 (  7.8%)
0 (  0.0%)      
38 ( 73.1%)   
3 (  5.8%)     
4 (  7.7%)     
6 ( 11.5%)   
1 (  1.9%)
77 ( 74.8%)
9 (  8.7%)
6 (  5.8%)
10 (  9.7%)





35 ( 68.6%)  
16 ( 31.4%)





Table 2: Demographic Characteristics of the Study Population
Age P-value from the ANOVA model with treatment as a factor. All other 
P-values were from the Fisher’s Exact Test.
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Period KNO3 Rinse Placebo P-value
Baseline 0.479
LS Mean 44.49 42.00
LS Std Err 2.50 2.45
Week 4 0.701
LS Mean -8.91 -10.34
LS Std Err 2.65 2.60
t-statistic 3.36 + 3.98+
Week 8 0.895
LS Mean -13.99 -13.49
LS Std Err 2.70 2.62
t-statistic 5.18+ 5.14+
Table 3: Subjective Assessment at Baseline and Post-Baseline: Reduction 
in Sensitivity
(+)  p< 0.001
Sensitivity was measured on a 100 mm visual analogue scale anchored 
at “no pain” to “intense pain”. Analysis was based on subject averages; 
P-values and least squares means from ANOVA model with treatment as 
a factor.  Post-baseline P-values and least squares means were adjusted for 
the baseline scores.
Period KNO3 Rinse Placebo P-value
Baseline .506  
LS Mean 54.60 53.09
LS Std Err 1.59 1.60
Week 4 .419
LS Mean -14.15 -11.08
LS Std Err 2.66 2.69
t-statistic -5.32+ -4.11+
Week 8 .628
LS Mean -17.15 -19.11
LS Std Err 2.81 2.89
t-statistic -6.10+ -6.62+
Table 4: Thermal Assessment at Baseline and Post-Baseline Reduction in 
Thermal Sensitivity
(+)  p< 0.001
Sensitivity was measured on a 100 mm visual analogue scale anchored at 
“no pain” to “intense pain”.
P-values and lest squares means were from a mixed linear model analysis 
with treatment as a factor.
Post-baseline P-values and least squares means were adjusted for the 
baseline scores.
Period KNO3 Rinse Placebo P-value
Baseline .055
LS Mean 19.06 20.21
LS Std Err .41 .42
Week 4 .113
LS Mean 6.79 3.60
LS Std Err 1.39 1.42
t-statistic 4.88+ 2.54*
Week 8 .031*
LS Mean 11.80 6.58
LS Std Err 1.66 1.71
t-statistic 7.12+ 3.85+
Table 5: Tactile Assessment at Baseline and Post-Baseline Differences: 
Increase in Tactile Sensitivity Threshold (gm)
(+) p<.001
(*) p<.05
Sensitivity threshold was measured in grams.  P-values and least squares 
means were from a mixed linear model analysis of the non-incisor teeth 
with treatment as a factor.  Post-baseline P-values and least squares means 
were adjusted for the baseline scores.
Period KNO3 Rinse Placebo P-value
Baseline .047 *
LS Mean 18.85 20.12
LS Std Err .44 .44
Week 4 .009 *
LS Mean 6.51 1.40
LS Std Err 1.33 1.34
Week 8 .008 *
LS Mean 11.74 4.81
LS Std Err 1.76 1.80
Table 6: Tactile Assessment at Baseline and Post-Baseline Differences: 
Increase in Tactile Sensitivity Threshold (g)  (for Subjects with at Least 3 
Threshold –Sensitive Teeth at Baseline - n = 75)
(*)p<.05 
Sensitivity measured in grams.  P-values and least squares means were 
from a mixed linear model analysis of the non-incisor teeth with treatment 
as a factor.  Post-baseline P-values and least squares means were adjusted 
for the baseline scores.
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